The Impact of Brain-Derived Neurotrophic Factor Polymorphism and Stimulation Parameters on the Response to Repetitive Transcranial Magnetic Stimulation: A Systematic Review

Yi-Ling Kuo, PT, PhD¹, Gracy Lin², Stephen J. Glatt, PhD^{3,4,5}

¹ Department of Physical Therapy Education, SUNY Upstate Medical University, Syracuse, NY

- ² Norton College of Medicine, SUNY Upstate Medical University, Syracuse, NY
- ³ Department of Psychiatry and Behavioral Sciences, SUNY Upstate Medical University, Syracuse, NY
- ⁴ Department of Neuroscience and Physiology, SUNY Upstate Medical University, Syracuse, NY
- ⁵ Department of Public Health and Preventive Medicine, SUNY Upstate Medical University, Syracuse, NY

ABSTRACT

Introduction: TMS has been a common technique used to stimulate neuromodulatory changes, which can have therapeutic effects. The underlying mechanism is still unknown, however it is thought to cause neuroplastic changes via LTD or LTP. However, the effects are highly variable, with demographics and baseline physiology thought to be playing a role.

Objectives: The purposes of this systematic review were to 1) examine how BDNF polymorphisms are related to the after-effects of rTMS in humans and 2) investigate the association between BDNF polymorphism and rTMS stimulation parameters as contributing factors to the response to rTMS.

Materials and Methods: Studies identified from PubMed, The Cochrane Library, and Embase were screened for eligibility. Data were extracted from the selected studies by one reviewer and verified by another reviewer. Risk of Bias was assessed using the Cochrane Collaboration's tool. Results were synthesized narratively.

Results: Of the 224 initial studies, 35 were included in this systematic review. 33 out of 35 studies had at least one domain of high or unclear risk of bias. 53% of the studies in healthy individuals showed differences in TMS-derived or behavioral measures between Val/Val homozygotes and Met allele carriers. The neuromodulatory effects were more reliable in Val/Val homozygotes than Met allele carriers. In stroke, neuromodulatory effects on corticospinal excitability and motor deficits were more evident in Val/Val homozygotes than Met allele carriers. Similarly, in depression, Val/Val homozygotes demonstrated more improvement in depression symptoms compared with Met allele carriers following rTMS. The role of BDNF polymorphism in other disorders remained unclear.

Conclusion: It remains inconclusive whether and how BDNF genotype impacts the effects of rTMS. Methodological heterogeneity in the stimulation parameters, such as dosage and excitatory or inhibitory protocols, interact with BDNF polymorphism and contribute to the response to rTMS.

Keywords: BDNF, Polymorphism, rTMS, Theta-burst stimulation, neuromodulation

INTRODUCTION

The rapid increase in the application of non-invasive brain stimulation (NIBS) has led to numerous breakthroughs in experimental and clinical neuroscience. Transcranial magnetic stimulation (TMS) has been the most used NIBS technique for studying cortical physiology and neuroplasticity. A high-current generator flows electrical current to the conducting coil and generates a magnetic field that induces an electric current to depolarize superficial axons and create action potentials in the cortex^{1,2}. The repetitive introduction of TMS pulses can alter brain function lasting for a period of time following the stimulation, typically tens of minutes, which is known as repetitive TMS (rTMS). The neuromodulatory effects of rTMS are dependent on the stimulation site, frequency, intensity of the magnetic pulses, and orientation of the coil. The consensus from the neuromodulation societies considers low-frequency stimulation of ≤ 1 Hz to be "inhibitory", whereas high-frequency stimulation of ≥ 5 Hz to be "excitatory" in modulating corticospinal excitability (CSE). The modified form of rTMS with a much higher stimulation frequency, called theta-burst stimulation (TBS), produces a longer-lasting neuromodulatory effect (up to 60 minutes) within a shorter stimulation time frame and at a lower intensity³. TBS is administered as a continuous (cTBS) train with inhibitory effects, or intermittent (iTBS) train with excitatory effects¹. It is generally acknowledged that TBS modifies CSE with a robust change similar to the cellular processing of long-term depression (LTD) with an inhibitory effect and long-term potentiation (LTP) with an excitatory effect^{1,4}.

The mechanism underlying the neuroplastic changes associated with the transient or lasting rTMSmodulated CSE remains unclear⁴. rTMS-induced neuromodulatory effects are highly variable and it has been demonstrated that only approximately 50% of participants responded to TBS with anticipated experimental and therapeutic effects⁵. Inter- and intra-individual variability of rTMS is dependent on baseline demographics and physiological characteristics such as anthropometric measurements of the head and brain, pathological changes in the central and peripheral nervous systems, and past life experiences leading to neuroplastic changes⁶. rTMS is used as a treatment to intervene in the brain circuits and has been shown to demonstrate efficacy in psychiatric and neurologic disorders⁷. Even though rTMS has been FDA-approved for a few indications, lacking markers to predict treatment efficacy is a long-standing issue in the field of neuromodulation. It is important to identify potential responders to rTMS to enhance the cost-effectiveness of this technique given the highly variable nature of this technique⁴. Predictor studies will help to pinpoint individuals suitable for rTMS intervention. Demographics, neurophysiology, and genetic traits have been studied. Using demographic, neurobiological, and clinical factors as predictors of rTMS treatment response is critical to fill the knowledge gap in identifying candidates to receive rTMS treatment.

Brain-derived neurotrophic factor (*BDNF*) is one of the candidate genes that contribute to brain morphological and functional changes and plays a critical role in synaptic plasticity and neuroprotection, integrating the metabolic and behavioral responses to the environments^{8,9}. The Val66Met (rs6265) variant is a functional nonsynonymous single nucleotide polymorphism (SNP) in the *BDNF* gene that encodes the *BDNF* protein on chromosome 11 (11p13). This SNP of *BDNF* is hypothesized to affect the heterogeneity of response to rTMS as the placement of Val or Met occurring at position 66 in the pro-region of the *BDNF* gene determines the distribution of *BDNF* in the brain¹⁰. As *BDNF* is essential in regulating synaptic plasticity and brain connectivity, the Val66Met polymorphism is associated with reduced activity-dependent *BDNF* release, which can lead to cognitive deficits and susceptibility to neurologic and psychiatric disorders^{11,12}. Another frequently studied *BDNF* polymorphism is C270T (rs56164415), a variant of a C to T substitution in the 5□ untranslated region that impacts the transcription of the *BDNF* gene. *BDNF* C270T alters the efficacy of *BDNF* translation, which can lead to *BDNF* in the brain¹³.

There are increasing studies suggesting that *BDNF* polymorphism is a vital factor in identifying responders to rTMS. However, there is conflicting evidence on the impact of *BDNF* genotype on responsiveness to rTMS, which might be attributed to various physiological factors and stimulation parameters. Here, this systematic review aims to 1) examine how the rs6265 and rs56164415 *BDNF* polymorphisms are related to the after-effects of rTMS in humans and 2) investigate the association between *BDNF* polymorphism and rTMS stimulation parameters as contributing factors to the response to rTMS.

MATERIALS AND METHODS

2.1 Protocol

The guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-analyses for Protocols 2015 (PRISMAm-P 2015) were used to conduct this systematic review. The protocol was registered in the PROSPERO.

2.2 Eligibility Criteria

Studies met the following eligibility criteria were included in this systematic review: (1) research in humans; (2) peer-reviewed studies published in English; (3) studies with accessible full-text; (4) original research; (5) participants classified and grouped according to *BDNF* genotype; (6) rTMS used as the non-invasive brain stimulation intervention; (7) outcomes measured pre and post rTMS

intervention to determine changes and treatment effects; (8) outcomes compared between groups with different *BDNF* genotypes or between groups receiving active and sham rTMS.

2.3 Search Strategy

Electronic literature searches were performed using PubMed, The Cochrane Library, and Embase, up to November 2024. These databases were searched using keywords and medical subject headings (MeSH), including: 'rTMS' or 'repetitive transcranial magnetic stimulation' or 'TBS' or 'theta burst stimulation' and '*BDNF*' or 'brain-derived neurotrophic factor' and 'polymorphism' or 'genotype'. Titles and abstracts of the initial search results were screened for relevant studies meeting the inclusion criteria. Full-text versions of potentially eligible studies were then examined. A manual search of the reference lists of the eligible studies was also performed.

2.4 Selection Process

One reviewer (YLK) initially screened the titles and abstracts of the articles, and the eligibility of the screened studies was determined independently by all reviewers.

2.5 Outcome Measures

The effects of rTMS or TBS on TMS-measured motor evoked potential (MEP) amplitudes were included as the neurophysiological outcomes. Outcomes other than TMS-derived measurements were included as behavioral outcomes or clinical outcomes.

2.6 Data Extraction

Demographic data extracted included the study population, sample size of each group, mean age, and sex. Brain stimulation-related data included the location of stimulation, side of stimulation (left or right hemisphere), stimulation protocol (stimulation frequency, session number, stimulation intensity, and number of stimuli), and sham stimulation. Methods of obtaining body fluid drawing and *BDNF* genotyping were extracted. Behavioral and clinical outcome measures obtained before and after rTMS or TBS were extracted. Data were independently extracted by one reviewer and verified by another reviewer (YLK and GL). The reviewers discussed any discrepancy in data to reach a consensus.

2.7 Risk of Bias

The Cochrane Collaboration's tool¹⁴ was used to assess the risk of bias in each included study. The domains assessed the risk of selection bias, performance bias, detection bias, attrition bias, reporting bias, and other biases. The ratings were categorized as low, unclear, or high risk of bias. The risk of

bias in each included study was independently assessed by one reviewer and verified by another reviewer (GL and YLK).

RESULTS

3.1 Selection of Studies

Electronic literature searches with keyword searches yielded a total of 224 studies. After removing the duplicates, 115 studies were included in the initial screening of titles and abstracts with the eligibility criteria. 74 studies were eliminated due to the following reasons: (1) studies were conference abstracts or proceedings (N = 16); (2) studies were reviews or commentaries (N = 18); (3) rTMS or TBS was not used as an intervention (N = 32); (4) articles were not written in English (N = 2); (5) records were protocol registrations (N = 6); (6) studies were performed in animals (N = 5); and (7) participants all had the same *BDNF* genotype and all received iTBS without a control condition (N = 1). As a result, 35 articles met the full eligibility criteria and were included in this systematic review. The selected studies were categorized according to population, including 17 studies in healthy individuals, nine in stroke, three in depression, one in spinocerebellar ataxia, one in Parkinson's Disease with levodopa-induced dyskinesias, one in Tourette syndrome, one in schizophrenia, one in autism spectrum disorder, and one with combined populations of older adults, Type-2 diabetes mellitus, and Alzheimer's disease. The PRISMA diagram (Figure 1) demonstrates the study inclusion process.

3.2 Risk of Bias

The risk of bias in the studies grouped by participant condition is presented in Figure 2. Risk of bias categories were "low risk of bias," "unclear risk of bias," or "high risk of bias." Most studies had a high or unclear risk of bias in three or more domains. Out of the total 35 studies, two had a high risk of bias for not using random sequence, five had a high risk of bias for not using allocation concealment, two had a high risk of bias for not blinding participants and researchers, one had a high risk of bias for not blinding outcomes assessment, 16 had a high risk of bias for incomplete outcome data, one had a high risk of selective reporting, and 17 had a high risk of other bias. Most studies did not include information regarding allocation concealment and blinding of outcome assessment. 33 out of 35 (94.3%) studies had at least one domain of unclear risk of bias.

3.3 BDNF Genotyping Methods

Twelve studies obtained saliva samples to perform *BDNF* genotyping^{15–26}, whereas other studies used venous blood samples. *BDNF* Val66Met polymorphisms were categorized as homozygous for valine in codon 66 (Val/Val), homozygous for methionine (Met), or Val/Met heterozygotes. Met/Met homozygotes

were less seen in the general population, and only four studies had sufficient sample size to group and compare participants across all polymorphisms (Val/Val versus Val/Met versus Met/Met)^{27–30}. Individuals with variants of Val/Met and Met/Met were pooled as Met allele carriers in some studies to refer to individuals with the Met variant form of *BDNF*^{16,20,25,31–40}. Only two studies genotyped the C270T polymorphisms: one in stroke³⁴ and one in schizophrenia⁴¹.

3.4 Stimulation Parameters, BDNF Polymorphism, and Responses to rTMS

Data extracted from the included studies are presented in Table 1. Low-frequency rTMS studies used 1 Hz, whereas high-frequency rTMS studies used 5, 10, and 20 Hz. TBS studies used 50 Hz as the stimulation frequency in both iTBS and cTBS. The stimulation sites included M1, frontal cortex, dorsal lateral prefrontal cortex (DLPFC), Broca's area, and cerebellum, with M1 being the most stimulated location. For single-session studies examining the immediate effects of rTMS and TBS, stimulation stimuli applied ranged from 250 to 1,500. For multi-session studies, rTMS and TBS were used as therapeutic interventions with neuromodulatory effects in some studies on stroke^{30,34,35,37,42} and depression^{39,43,44}, as well as other disorders^{26,41,45}. The treatment courses were five to 22 sessions over one to three weeks, with stimulation stimuli ranging from 300 to 1,800 per session.

Healthy Individuals

Most studies in healthy individuals targeted the left M1 at the representational area of the first dorsal interosseus (FDI) muscle, whereas some studies targeted the dominant M1 of the pharyngeal muscle¹⁷, dominant³² or non-dominant²⁷ M1 of the FDI, right DLPFC¹⁵, and left frontal cortex¹⁶. Five studies administered rTMS (high and/or low frequency)^{15–17,27,31}, and 14 studies administered TBS (iTBS and/or cTBS)^{18–22,28,29,31–33,46–49}. Sub-threshold^{16,17,27,34–37,42}, at-threshold^{15,30,39}, or supra-threshold^{17,27,30,31,36,39,41,43,44} intensities were used in rTMS protocols, ranging from 90% to 120% resting motor threshold (RMT) or motor threshold (MT) without specifying muscle activation status. TBS protocols, including iTBS and cTBS, used an 80% active motor threshold (AMT) as the stimulus intensity, except for one study using 80% RMT²⁸.

Most studies used a single-session cross-sectional design to investigate the acute effects of rTMS or TBS. MEP amplitude was the most commonly used outcome measure to capture brain physiology^{17–22,27–29,31–33,46,47,49}, while some studies reported the neuromodulatory effects with other physiological parameters such as MEP latency^{17,27}, RMT^{27–29}, AMT²⁹, short-interval intracortical inhibition¹⁸, intracortical facilitation¹⁸, and motor map²⁸. Behavior outcomes measuring cognitive function were used in two rTMS studies^{15,16}. Some studies showed that neuromodulatory effects were less observed in Met allele carriers compared to Val/Val homozygotes^{17,18,22,27,32}. Val/Val homozygotes

demonstrated more reliable neuromodulatory effects (excitatory or inhibitory) than Met allele carriers^{21,22,26}. Alterations in behaviors measured by cognitive performance were evident in Val/Val homozygotes but not in Met allele carriers^{15,16}. However, 47% of the studies in healthy individuals did not observe differences in neuromodulatory effects between Val/Val homozygotes and Met allele carriers, of which one study used rTMS³¹, seven studies used iTBS^{20,28,29,31,46,47,49}, and three studies used cTBS^{29,33,46}.

Stroke

In stroke, three studies used high-frequency (10 Hz) rTMS at the ipsilesional M1^{35,36,42}; two used low-frequency rTMS at the contralesional M1^{34,37}; one used iTBS at the ipsilesional M1³⁸; and two used cTBS at the right M1^{23,24}. Only one study targeted the right DLPFC with low-frequency rTMS³⁰. Neuromodulatory effects on CSE were greater in Val/Val homozygotes compared to Met allele carriers^{23,36}. Motor impairments of the upper limb measured by the Fugl Meyer Assessment and Box and Block Test were improved with excitatory high-frequency rTMS applied to the ipsilesional M1 in Val/Val homozygotes compared to Met allele carriers^{35,42}, which was not observed with inhibitory low-frequency rTMS applied to the contralesional M1³⁷. Inhibitory cTBS reduced aphasia more in Val/Val homozygotes than Val/Met heterozygotes²⁴. However, *BDNF* polymorphism has no impact on the CSE, *BDNF* concentration, and cognitive symptoms following low-frequency rTMS^{30,34} or iTBS³⁸ in stroke.

Depression

All three studies on depression stimulated the DLPFC, and two studies targeted the left^{39,43} while one targeted the right DLPFC⁴⁴. Low-frequency rTMS^{43,44}, high-frequency rTMS^{39,43}, and iTBS³⁹ were used in these studies on depression. Stimulation intensities ranged from 100% to 110% RMT in rTMS studies^{39,43,44}. A total of five to 10 sessions were administered with the number of stimulation stimuli ranging from 300 to 1800 per session. All rTMS studies showed more improvement in depression symptoms (measured by the Hamilton Depression Rating Scale) in Val/Val homozygotes than Met allele carriers^{39,43,44}, whereas *BDNF* polymorphisms did not affect the change of depression symptoms following iTBS³⁹.

Other Disorders

In studies on disorders other than stroke or depression, iTBS or cTBS was used on the left M1 of the FDI^{25,26,40}. Two studies used iTBS⁴⁵ or cTBS⁵⁰ targeting the cerebellum, and one used high-frequency rTMS on the left DLPFC⁴¹. There were various outcome measures used to capture the neuromodulatory effects of rTMS and TBS, including physiological measures such as MEP amplitudes

and RMT, and behavioral or clinical measures of symptoms. One study in Parkinson's Disease with levodopa-induced dyskinesias⁵⁰ and another study in Spinocerebellar Ataxia 38⁴⁵ demonstrated greater neuromodulatory responses on serum *BDNF* with Val/Val homozygotes compared to Val/Met heterozygotes. Nonetheless, studies on Gilles de la Tourette syndrome and Spinocerebellar Ataxia 38 did not find different responses to TBS in clinical symptoms and MEP amplitudes between Val/Val homozygotes and Met allele carriers^{40,45}. In this systematic review, only one study demonstrated greater neuromodulatory effects in Met allele carriers than Val/Val homozygotes after pooling the data from Alzheimer's disease, Type-2 diabetes mellitus, and controls²⁶. Val/Met heterozygotes may result in more variability in the response to neuromodulation, which is consistent with the finding of another study in healthy individuals²¹.

DISCUSSION

This systematic review investigated the impact of *BDNF* genotypes, including the rs6265 and rs56164415, on the response to rTMS or TBS in the literature of human research. There was high heterogeneity in the research methodology across studies. 12 out of 23 (52.2%) of the rTMS or TBS protocols in healthy individuals demonstrated greater neuromodulatory effects with rTMS or TBS on neurophysiological measures such as MEP amplitude and behavioral measures of cognitive performance, in Val/Val homozygotes than Met allele carriers. 3 out of 10 (30.0%) protocols in stroke showed greater neuromodulatory effects on physiological measures like MEP amplitude or peripheral *BDNF* serum concentration, and another 30% of protocols showed more improvement in clinical outcomes with symptom improvement in Val/Val homozygotes compared to Met allele carriers. 4 out of 5 protocols in depression demonstrated more improvement in clinical outcomes with symptom improvement in Val/Val homozygotes compared to Met allele carriers. 11 out of 23 (47.8%) rTMS or TBS protocols in healthy individuals and 4 out of 10 (40.0%) protocols in stroke did not demonstrate different responses to rTMS or TBS in any outcome measures with the Val66Met polymorphism. The impact of *BDNF* Val66Met polymorphisms on other disorders was mixed.

4.1 Dosage

Determining appropriate dosage in the use of neuromodulation has been challenging due to a lack of standard definition of dosage⁵¹. The total number of pulses is the most common method of determining the dosage of TMS, while other parameters, such as stimulation intensity, stimulation frequency, and trial session number, contribute to the dose-response algorithm^{51–53}. To date, the interaction between *BDNF* polymorphism and dosage of TMS has not been systematically investigated. Dosage can be discussed in two categories in the studies included in this systematic review: 1) immediate effect with a

single session of neuromodulation and 2) therapeutic effect with multiple neuromodulation sessions. All studies in healthy individuals were designed to investigate the immediate effect of rTMS/TBS with a single session, and the number of stimuli ranged from 250 to 1500. Five protocols for stroke and five protocols for other disorders used a single-session design, with the number of stimuli ranging from 600 to 1000. Single-session rTMS/TBS has not been shown to consistently modulate CSE in healthy individuals⁵⁴. Similarly, the current systematic review also showed that the number of stimuli did not appear to contribute to the differences observed between *BDNF* genotypes with the immediate after-effects of rTMS/TBS.

For multiple-session studies, five protocols for stroke, five protocols for depression, and two protocols for other disorders used five to 22 sessions to build up therapeutic effects with rTMS/TBS. There was high variability in the total number of stimuli used across these studies, between 2000 and 27000. Surprisingly, a lower total number of stimuli (10000 or less) appeared to be associated with differences observed in MEP amplitude and clinical outcomes between *BDNF* genotypes^{35,42–44}, whereas a larger total number of stimuli (more than 10000) was associated with insignificant between-genotype differences^{30,34,37,39,45}. It is possible that the influence of the *BDNF* polymorphism can be overcome by increasing the dosage with a large total number of stimuli to achieve the modulatory effects. However, *BDNF* polymorphism effects were not attenuated by higher dosages from increased stimulation intensity (100% RMT or higher)^{15,17,27,36,39,41,43,44}.

4.2 Forms of rTMS

Theta burst stimulation, a modified form of rTMS, generates more substantial neuromodulatory effects in modulating CSE and synaptic plasticity than conventional rTMS^{2,55}. It has been shown that the iTBS leads to longer-lasting increased CSE than high-frequency rTMS. Similarly, cTBS leads to longer-lasting decreased CSE than low-frequency rTMS, although the effects are less consistent than iTBS². A previous systematic review and meta-analysis examined how *BDNF* polymorphism influenced TBS effects and demonstrated larger effect sizes in Val/Val homozygotes. Met allele carriers, on the other hand, demonstrated variable results in response to TBS⁵³. Two studies included in the current systematic review demonstrated variable findings in Met allele carriers and also used TBS^{21,26}. In studies with both rTMS and TBS protocols, one study in healthy individuals did not find *BDNF* polymorphism to impact CSE with either protocol³¹, whereas another study in depression showed that the depression symptoms reduced in Val/Val homozygotes but not Met allele carriers only with rTMS³⁹. Overall, *BDNF* polymorphism influences response to neuromodulation in 14 out of 19 studies in rTMS

and 14 out of 26 studies in TBS. It is possible that the impact of the *BDNF* polymorphism could be attenuated by a modified yet intensive form of rTMS.

4.3 Excitatory versus Inhibitory Protocols

There were conflicting findings on the consistency in modulating CSE with the excitatory versus inhibitory protocols in rTMS⁵⁶ and TBS^{53,57}. There are known demographic and personal factors contributing to the neuromodulatory effects of long-term depression and long-term potentiation, including *BDNF* polymorphism^{9,58}. In the current systematic review, the *BDNF* polymorphism effect was evident in similar percentages of studies in excitatory and inhibitory protocols. Overall, 16 out of 26 (61.5%) excitatory protocols (including high-frequency rTMS and iTBS) and 13 out of 19 (68.4%) inhibitory protocols (including low-frequency rTMS and cTBS) demonstrated a BDNF polymorphism effect on the response to neuromodulation. A previous systematic review, which only included healthy individuals, found approximately 20-30% of studies showed BDNF polymorphism-related changes in MEP⁵⁹. When considering only the studies with healthy individuals in the current systematic review, 12 out of 23 (52.2%) protocols (excitatory: 6; inhibitory: 6) demonstrated BDNF polymorphism-related changes, which is considerably more than the previous systematic review⁵⁹. This is possibly due to diverse statistical approaches, as the previous systematic review only considered the results of ANOVA to determine whether there was a BDNF polymorphism effect, while the current study included any statistical analyses showing differences in outcome measures between BDNF genotypes. Another systematic review and meta-analysis study in healthy individuals indicated that the effects of TBS (including both iTBS and cTBS) favored Val/Val homozygote over Met allele carriers, with the excitatory iTBS showing greater effect sizes⁵³. While the current systematic review did not compare the effect sizes across the included studies, we expanded the scope to also include pathological populations beyond healthy individuals. A BDNF polymorphism effect was evident in 17 out of 22 (77.3%) protocols in pathological populations, with a marginally higher percentage in the excitatory (10 out of 12, 83.3%) compared to inhibitory (7 out of 10, 70%) protocols.

4.4 Methodological Considerations

The methodologies and stimulation parameters used in the included studies were variable, likely due to a lack of consensus on optimal protocols in rTMS and TBS research. While the stimulation intensity, stimulation frequency, and pulse number used for TBS were consistent in most studies (80% AMT, 50 Hz, and 600 pulses, respectively), these three parameters were more variable in rTMS studies. Although the consistency of stimulation parameters reduced variability resulting from the neuromodulation device, of the 26 TBS protocols, only 14 studies (53.8%) showed significant *BDNF* polymorphism effects. Personal factors such as symptom severity and demographics need to be taken into account as possible predictors of rTMS responsiveness.

Some commonly used outcome measures were not completely comparable given the different scales or units (e.g., MEP amplitude measured with the original unit in mV, percentage difference, or log-transformed; Hamilton rating scale for depression in 21 versus 17 items). Some studies segregated participants with Val/Met heterozygotes and Met/Met homozygotes as different genotypes, whereas others grouped them as Met allele carriers since there were often not enough data points with the Met/Met homozygotes. This precludes inferring the association between response to rTMS and Val/Met heterozygotes.

As for stimulation sites, there were not enough studies using hotspots other than M1 in studies with healthy individuals, and thus whether brain region influences *BDNF* polymorphism effects remain inconclusive. In stroke, *BDNF* polymorphism effects were more apparent when targeting the ipsilesional M1 with high-frequency rTMS^{35,36,42} compared to targeting the contralesional M1 with low-frequency rTMS^{30,34,37} or ipsilesional iTBS³⁸. Facilitating the post-stroke ipsilesional hemisphere or inhibiting the contralesional hemisphere was based on the interhemispheric imbalance model that hypothesizes asymmetric interhemispheric inhibition⁶⁰. While administering low-frequency rTMS at the contralesional M1 and high-frequency rTMS at the ipsilesional M1 have been recommended by the most recent guidelines on the therapeutic use of rTMS⁷, it is possible that Met allele carriers are less responsive to high-frequency rTMS and therefore *BDNF* polymorphism should be considered while determining the rTMS protocol to enhance post-stroke motor recovery.

In the risk of bias assessments, lack of allocation concealment was often seen in the included studies, or there was no description of whether the investigators performing TMS-derived assessments were aware of the rTMS/TBS protocol. Other common biases included no blinding of the participants receiving different protocols of rTMS, and incomplete reports of stimulation parameters and the original values of group means in TMS-derived outcomes. Most of the studies (94.3%) did not report procedures or data in at least one domain of risk of bias assessment. These were rated as unclear risk of bias and further contributed to potential bias while interpreting the findings.

4.5 Limitations and Future Directions

Some limitations of this systematic review are noted. First, only two studies examined the *BDNF* C270T polymorphism; therefore, there was not enough data to conclude the relationship between C270T

polymorphism and response to neuromodulation. Second, most included studies had small sample sizes of less than 50 participants. It is possible that some studies were underpowered with insignificant differences in outcome measures with classification according to *BDNF* genotypes or assignments to receive different rTMS protocols. Third, while *BDNF* polymorphism as a contributing factor to rTMS modulatory effects was widely studied in healthy individuals, there were insufficient publications in people with medical conditions. Quantitative data analysis was limited by the small number of studies, heterogeneity of patient characteristics, unretrievable data of key parameters, and inconsistency of rTMS protocols. Future studies are warranted to explore interactions between *BDNF* polymorphism and rTMS parameters and dosages while controlling participant-specific factors, such as symptom severity, in populations with medical conditions.

REFERENCES

- 1. Lefaucheur, J. P. *et al.* Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS). *Clinical Neurophysiology* vol. 125 2150–2206 Preprint at https://doi.org/10.1016/j.clinph.2014.05.021 (2014).
- 2. Rossini, P. M. *et al.* Non-invasive electrical and magnetic stimulation of the brain, spinal cord, roots and peripheral nerves: basic principles and procedures for routine clinical and research application. An updated report from an I.F.C.N. Committee. *Clinical Neurophysiology* **126**, 1071–1107 (2015).
- 3. Huang, Y. Z., Edwards, M. J., Rounis, E., Bhatia, K. P. & Rothwell, J. C. Theta burst stimulation of the human motor cortex. *Neuron* **45**, (2005).
- 4. Pellegrini, M., Zoghi, M. & Jaberzadeh, S. Biological and anatomical factors influencing interindividual variability to noninvasive brain stimulation of the primary motor cortex: A systematic review and meta-analysis. *Rev Neurosci* **29**, (2018).
- 5. López-Alonso, V., Cheeran, B., Río-Rodríguez, D. & Fernández-Del-Olmo, M. Inter-individual variability in response to non-invasive brain stimulation paradigms. *Brain Stimul* **7**, (2014).
- 6. Krause, B. & Kadosh, R. C. Not all brains are created equal: The relevance of individual differences in responsiveness to transcranial electrical stimulation. *Frontiers in Systems Neuroscience* vol. 8 Preprint at https://doi.org/10.3389/fnsys.2014.00025 (2014).
- 7. Lefaucheur, J. P. *et al.* Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): An update (2014–2018). *Clinical Neurophysiology* vol. 131 474–528 Preprint at https://doi.org/10.1016/j.clinph.2019.11.002 (2020).
- 8. Kotlęga, D., Peda, B., Zembroń-Łacny, A., Gołąb-Janowska, M. & Nowacki, P. The role of brain-derived neurotrophic factor and its single nucleotide polymorphisms in stroke patients. *Neurol Neurochir Pol* **51**, 240–246 (2017).
- 9. Suppa, A. & Cheeran, B. Further insights into the effect of BDNF genotype on non-invasive brain stimulation. *Clin Neurophysiol* **126**, 1281–1283 (2015).
- 10. Saghazadeh, A., Esfahani, S. A. & Rezaei, N. Genetic polymorphisms and the adequacy of brain stimulation: state of the art. *Expert Review of Neurotherapeutics* vol. 16 Preprint at https://doi.org/10.1080/14737175.2016.1194202 (2016).
- 11. McHughen, S. A. *et al.* BDNF val66met polymorphism influences motor system function in the human brain. *Cerebral Cortex* **20**, (2010).
- 12. Bath, K. G. & Lee, F. S. Variant BDNF (Val66Met) impact on brain structure and function. *Cognitive, Affective and Behavioral Neuroscience* vol. 6 Preprint at https://doi.org/10.3758/CABN.6.1.79 (2006).
- 13. Watanabe, Y., Nunokawa, A. & Someya, T. Association of the BDNF C270T polymorphism with schizophrenia: Updated meta-analysis. *Psychiatry Clin Neurosci* **67**, (2013).
- 14. Higgins, J. P. T. *et al.* The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ* **343**, (2011).
- 15. Tulviste, J. *et al.* BDNF polymorphism in non-veridical decision making and differential effects of rTMS. *Behavioural Brain Research* **364**, (2019).
- 16. Abellaneda-Pérez, K. *et al.* BDNF Val66Met gene polymorphism modulates brain activity following rTMS-induced memory impairment. *Sci Rep* **12**, (2022).

- 17. Jayasekeran, V. *et al.* Val66Met in brain-derived neurotrophic factor affects stimulusinduced plasticity in the human pharyngeal motor cortex. *Gastroenterology* **141**, (2011).
- 18. Andrews, S. C. *et al.* Intensity Matters: High-intensity Interval Exercise Enhances Motor Cortex Plasticity More Than Moderate Exercise. *Cerebral Cortex* **30**, (2020).
- 19. Jannati, A., Block, G., Oberman, L. M., Rotenberg, A. & Pascual-Leone, A. Interindividual variability in response to continuous theta-burst stimulation in healthy adults. *Clinical Neurophysiology* **128**, (2017).
- 20. Gomes-Osman, J. *et al.* The effects of exercise on cognitive function and brain plasticity a feasibility trial. *Restor Neurol Neurosci* **35**, (2017).
- 21. Harvey, D. Y. *et al.* Variability in cTBS Aftereffects Attributed to the Interaction of Stimulus Intensity With BDNF Val66Met Polymorphism. *Front Hum Neurosci* **15**, (2021).
- 22. Jannati, A. *et al.* Test-retest reliability of the effects of continuous theta-burst stimulation. *Front Neurosci* **13**, (2019).
- 23. Parchure, S. *et al.* Brain-Derived Neurotrophic Factor Gene Polymorphism Predicts Response to Continuous Theta Burst Stimulation in Chronic Stroke Patients. *Neuromodulation* **25**, (2022).
- 24. Dresang, H. C. *et al.* Genetic and Neurophysiological Biomarkers of Neuroplasticity Inform Post-Stroke Language Recovery. *Neurorehabil Neural Repair* **36**, (2022).
- 25. Jannati, A. *et al.* Modulation of motor cortical excitability by continuous theta-burst stimulation in adults with autism spectrum disorder. *Clinical Neurophysiology* **132**, (2021).
- 26. Fried, P. J., Jannati, A., Davila-Pérez, P. & Pascual-Leone, A. Reproducibility of single-pulse, paired-pulse, and intermittent theta-burst TMS measures in healthy aging, Type-2 diabetes, and Alzheimer's disease. *Front Aging Neurosci* **9**, (2017).
- 27. Hwang, J. M., Kim, Y. H., Yoon, K. J., Uhm, K. E. & Chang, W. H. Different responses to facilitatory rTMS according to BDNF genotype. *Clinical Neurophysiology* **126**, (2015).
- Lee, M. *et al.* Interaction of Motor Training and Intermittent Theta Burst Stimulation in Modulating Motor Cortical Plasticity: Influence of BDNF Val66Met Polymorphism. *PLoS One* 8, (2013).
- 29. Guerra, A. *et al.* Gamma-transcranial alternating current stimulation and theta-burst stimulation: inter-subject variability and the role of BDNF. *Clinical Neurophysiology* **131**, (2020).
- 30. Lu, H., Zhang, T., Wen, M. & Sun, L. Impact of repetitive transcranial magnetic stimulation on post-stroke dysmnesia and the role of BDNF Val66Met SNP. *Med Sci Monit* **21**, 761–8 (2015).
- 31. Li Voti, P. *et al.* Correlation between cortical plasticity, motor learning and BDNF genotype in healthy subjects. *Exp Brain Res* **212**, (2011).
- 32. Cheeran, B. *et al.* A common polymorphism in the brain-derived neurotrophic factor gene (BDNF) modulates human cortical plasticity and the response to rTMS. *Journal of Physiology* **586**, (2008).
- 33. McDonnell, M. N., Buckley, J. D., Opie, G. M., Ridding, M. C. & Semmler, J. G. A single bout of aerobic exercise promotes motor cortical neuroplasticity. *J Appl Physiol* **114**, (2013).
- 34. Mirowska-Guzel, D. *et al.* Association between BDNF-196 G>A and BDNF-270 C>T polymorphisms, BDNF concentration, and rTMS-supported long-term rehabilitation outcome after ischemic stroke. *NeuroRehabilitation* **32**, (2013).

- 35. Chang, W. H. *et al.* BDNF polymorphism and differential rTMS effects on motor recovery of stroke patients. *Brain Stimul* **7**, (2014).
- 36. Uhm, K. E., Kim, Y. H., Yoon, K. J., Hwang, J. M. & Chang, W. H. BDNF genotype influence the efficacy of rTMS in stroke patients. *Neurosci Lett* **594**, (2015).
- 37. Niimi, M. *et al.* Role of brain-derived neurotrophic factor in beneficial effects of repetitive transcranial magnetic stimulation for upper limb hemiparesis after stroke. *PLoS One* **11**, (2016).
- 38. Di Lazzaro, V. *et al.* Val66Met BDNF gene polymorphism influences human motor cortex plasticity in acute stroke. *Brain Stimul* **8**, 92–96 (2015).
- Cheng, C. M. *et al.* Predictive roles of brain-derived neurotrophic factor Val66Met polymorphism on antidepressant efficacy of different forms of prefrontal brain stimulation monotherapy: A randomized, double-blind, sham-controlled study. *J Affect Disord* 297, (2022).
- 40. Marsili, L. *et al.* BDNF and LTP-/LTD-like plasticity of the primary motor cortex in Gilles de la Tourette syndrome. *Exp Brain Res* **235**, (2017).
- 41. Su, X. *et al.* Neuronavigated Repetitive Transcranial Stimulation Improves Neurocognitive Functioning in Veterans with Schizophrenia: A Possible Role of BDNF Polymorphism. *Curr Neuropharmacol* **21**, 142–150 (2023).
- 42. Chang, W. H., Uhm, K. E., Shin, Y. II, Pascual-Leone, A. & Kim, Y. H. Factors influencing the response to high-frequency repetitive transcranial magnetic stimulation in patients with subacute stroke. *Restor Neurol Neurosci* **34**, (2016).
- 43. Bocchio-Chiavetto, L. *et al.* 5-HTTLPR and BDNF Val66Met polymorphisms and response to rTMS treatment in drug resistant depression. *Neurosci Lett* **437**, (2008).
- 44. Krstić, J. *et al.* Low-frequency repetitive transcranial magnetic stimulation in the right prefrontal cortex combined with partial sleep deprivation in treatment-resistant depression: A randomized sham-controlled trial. *Journal of ECT* **30**, (2014).
- 45. Sanna, A. *et al.* Therapeutic Use of Cerebellar Intermittent Theta Burst Stimulation (iTBS) in a Sardinian Family Affected by Spinocerebellar Ataxia 38 (SCA 38). *Cerebellum* **21**, (2022).
- 46. Mastroeni, C. *et al.* Brain-Derived Neurotrophic Factor A Major Player in Stimulation-Induced Homeostatic Metaplasticity of Human Motor Cortex? *PLoS One* **8**, (2013).
- 47. Antal, A. *et al.* Brain-derived neurotrophic factor (BDNF) gene polymorphisms shape cortical plasticity in humans. *Brain Stimul* **3**, (2010).
- 48. Moliadze, V., Fritzsche, G. & Antal, A. Comparing the efficacy of excitatory transcranial stimulation methods measuring motor evoked potentials. *Neural Plast* **2014**, (2014).
- 49. Antal, A. *et al.* BDNF Gene Polymorphisms and Motor Cortical Plasticity in Healthy Humans: When Should We Consider It. *J Neurosci Rehabil* **1**, (2014).
- 50. Sanna, A. *et al.* Cerebellar continuous theta burst stimulation reduces levodopa-induced dyskinesias and decreases serum BDNF levels. *Neurosci Lett* **716**, (2020).
- 51. Sabé, M. *et al.* Transcranial Magnetic Stimulation and Transcranial Direct Current Stimulation Across Mental Disorders: A Systematic Review and Dose-Response Meta-Analysis. *JAMA Netw Open* **7**, (2024).
- 52. Yang, C. et al. Repetitive transcranial magnetic stimulation therapy for motor recovery in Parkinson's disease: A Meta-analysis. *Brain and Behavior* vol. 8 Preprint at https://doi.org/10.1002/brb3.1132 (2018).

- 53. Chung, S. W., Hill, A. T., Rogasch, N. C., Hoy, K. E. & Fitzgerald, P. B. Use of theta-burst stimulation in changing excitability of motor cortex: A systematic review and meta-analysis. *Neurosci Biobehav Rev* **63**, 43–64 (2016).
- 54. Hiscock, A., Miller, S., Rothwell, J., Tallis, R. C. & Pomeroy, V. M. Informing dose-finding studies of repetitive transcranial magnetic stimulation to enhance motor function: A qualitative systematic review. *Neurorehabil Neural Repair* **22**, (2008).
- 55. Rachid, F. Safety and efficacy of theta-burst stimulation in the treatment of psychiatric disorders: A review of the literature. *Journal of Nervous and Mental Disease* vol. 205 Preprint at https://doi.org/10.1097/NMD.00000000000742 (2017).
- 56. Prei, K. *et al.* Limited evidence for reliability of low and high frequency rTMS over the motor cortex. *Brain Res* **1820**, (2023).
- 57. Wischnewski, M. & Schutter, D. J. L. G. Efficacy and Time Course of Theta Burst Stimulation in Healthy Humans. *Brain Stimul* **8**, 685–692 (2015).
- 58. Silverstein, W. K. *et al.* NEUROBIOLOGICAL PREDICTORS of RESPONSE to DORSOLATERAL PREFRONTAL CORTEX REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION in DEPRESSION: A SYSTEMATIC REVIEW. *Depress Anxiety* **32**, (2015).
- 59. Sasaki, R. *et al.* Influence of brain-derived neurotrophic factor genotype on short-latency afferent inhibition and motor cortex metabolites. *Brain Sci* **11**, (2021).
- 60. Boddington, L. J. & Reynolds, J. N. J. Targeting interhemispheric inhibition with neuromodulation to enhance stroke rehabilitation. *Brain Stimulation* vol. 10 Preprint at https://doi.org/10.1016/j.brs.2017.01.006 (2017).

FIGURE CAPTIONS

Figure 1. PRISMA diagram of the review

Figure 2. Risk of bias assessments showing the percentage of included studies with high, unclear, or low risk of bias in the population of A. healthy individuals; B. stroke; C. depression; and D. other disorders.

Tabl	e 1. Data extract	ion.												
		Age, Sex,			rTMS		S	timulation pa	rameters		BDNF	Outcome	Comparisons between	
#	Stu dy	Disease Characteristics	Gen otyped s	sample size	type	Placement	Frequenc y	Intensity	Pulse number/ Duration		Sample	measures	BDNF genotypes in response to rTMS or TBS	was r
						Healthy individ	luals (17 stud	ies, 23 protoc	ols)					
			Val/Val	14			5 Hz 50 Hz		1 session per condition, 3 conditions with counterbalance d order,	1,500 (10 stimuli/train,			NS	ertified
1	Li Voti et al.	27.95 ± 5.57	Met allele carriers	7	rTMS	Left M1 (FDI)		RMT		15 trains, intertrain interval: 1–2 min)	Blood	MEP amplitude		by peer n It i
	(2011)	16 F, 22 M	Val/Val	14						600 (2 sec of train. 20 trains				s ma
			Met allele carriers	7	iTBS	Left M1 (FD		80% AMT	2 weeks apart	in every 200 ms, intertrain interval: 8 sec)	Blood	MEP amplitude	NS	<mark>w) is the</mark> de availa
			Val/Val	15	rTMS		5 Hz	90% RMT	250 (5 trains intertrain int	5 trains of 50 pulses, train interval: 10 sec)		MEP amplitude,	Reduced MEP latency in Val/Met compared	<u>author/f</u> ble und
2	Jayasekera	60±20	Val/Met	7		Dominant M1 (pharyngeal)			1 ses	ssion	saliva	Tatency	to Val/Val	unde er a
	(2011)	15 F, 7 M	Val/Val	16	rTMS		1 Hz	120%	600 (10 minut e	s of stimulation)	Mixed: Blood	MEP amplitude.	Reduced inhibitory modulatory effects in	er, who
			Val/Met	6				RMT	1 ses	ssion	or saliva	latency	Val/Met compared to Val/Val	-NC
		29.1 ± 4.2 7 F, 5 M	Val/Val 12			Non-	10 Hz	90% RMT	1,000 (20 trains, intertrain interval: 55 sec) 1 session per condition, 3			MEP	Reduced excitatory	grante ND 4.
3	Hwang et al. (2015)	26.6 ± 2.8 12 F, 7 M	Val/Met	19	rTMS	dominant M1 (FDI)	10 Hz 110% RMT				Blood	amplitude, latency,	Met/Met following both sub- and supra-threshold	o Inte
		26.4 ± 3.7 7 F, 2 M	Met/Met	9			Sham (un	specified)	conditions with 24 hr washout period			RMT	rTMS.	dRxiv
		30.66 ± 7.85 3 F, 6 M	Val/Val	9			1 Hz	100% RMT	360 (6	5 min)			Following rTMS, Val/Val were more context-	a lice
4	Tulviste et al. (2019)	35.00 ± 3.46 5 F, 2 M	Val/Met	7	rTMS	R DLPFC	Sham (coil	titled 90°)	1 session per condition		Saliva	Cognitive Bias task	dependent, whereas Val/Met were more context-independent	ense to di
			Val/Val	24					1,296 (last 900 ms synchronized with a cognitive encoding task: 0.9 sec * 20 Hz* 6 blocks * 12 pictures) 1 session per condition, 3 conditions with 1 day apart [cited protocol of Martin-Trias et al. (2018)]					splay
5	Abellaneda ଅPérez et al. (2022)	23.47 ± 3.5 0 F, 43 M	Met allele carriers	19	rTMS	L frontal cortex Cranial vertex (control)	20 Hz	90% RMT			Saliva	Cognitive performanc e fMRI BOLD activation	rTMS over frontal cortex decreased cognitive performance in Val/Val bu not in Met carriers	the preprint in perp
6	Cheeran et al. (2008)	26.45 ± 5 5 F, 4 M	Val/Val	9	cTBS	Dominant M1 (FDI)	50 Hz	80% AMT	300 (sequences o rate of 5 Hz	of 100 bursts at a for 20 sec)	Blood	MEP amplitude	Corticom otor excitability decreased in Val/Val compared to Met allele	petuity.

		26.45 ± 5	Met allele	٩					1 se	ssion			carriers.
	_	5 F, 4 M	carriers	5									
	_	29.3 ± 3 3 F, 6 M	Val/Val	9	_	Dominant M1			600 (2 sec train r	epeated every 10		MED	Corticomotor excitability increased in Val/Val
		28.7 ± 3 3 F, 6 M	Met allele carriers	9	iTBS	(FDI)	50 Hz	80% AMT	1 se	ssion		amplitude	Met carriers responded t neuromodulation less tha Val/Val
	Antal et al.	21 to 32 7 F, 3 M	Val/Val	10		Left M1 (FD)	E0.11-	80% AMT	600 (3-pulse bursts repeated at 200 ms, 2-sec train of TBS for 190		6	MEP	,
	(2010)	20 to 29 3F, 2M	Val/Met	5	TBS	or ADM)	50 Hz	80% AMT	sec, intertrain i 1 se:	nterval: 10 sec) ssion	Blood	amplitude	NS
		29.6 ± 3.6 2 E 4 M	Val/Val	6					600 (3-nulse bu	rsts reneated at		Motor	
	Lee et al.	32.5 ± 4.7	Val/Met	13	TRS		50 47	80% PMT	200 ms, 2-sec tra	200 ms, 2-sec train of TBS for 190 sec, intertrain interval: 10 sec)		e, motor	NIC
	(2013) -	31.3±5.3 2 F, 2 M	Met/Met	4			50112	80% NWT	1 se:	ssion	BIOOU	MEP amplitude,	CN
			Val/Val	17								motor map	
	Mastroeni et al. (2013)			17	iTBS	L M1 (FDI)	50 Hz	80% AMT	1 session per condition, 3	600 (3-pulse bursts repeated at 200 m s, 2- sec train of TBS	Blood	MEP amplitude	NS
		26.0±3.2 0 F, 29 M	Val/Met	12					conditions in pseudorandomi zed order with at least 5 days	for 190 sec, intertrain interval: 10 sec)			
			Val/Val	17	- cTBS	L M1 (EDI)	50 Hz	80% AMT	apurt	600 (3-pulse bursts repeated at 200 ms 40-	Blood	MEP	NS
			Val/Met	12			00112			sec train of TBS)	51000	amplitude	
	McDonnell	27.8 ± 7.9 6 F, 4 M	Val/Val	10					600 (3-pulse bu 200 ms, 40-se	rsts repeated at c train of TBS)		M-wave	
	et al. (2013)	26.1 ± 8.4 10 F, 5 M	Met allele carriers	15	cTBS	L M1 (FDI)	50 Hz	80% AMT	1 session per condition, 3 conditions with at least 1 wk apart		Blood	MEP	NS
Antol et al	Age N/A 10F, 5 M	Val/Val	15					600 (3-pulse bursts repeated at 200 ms intervals. 2-sec train for					
	(2014)	Age N/A 6F, 2M	Val/Met	8	iTBS	ADM)	50 Hz	80% AMT	190 sec, intertrai 1 se	n interval: 10 sec) ssion	Blood	amplitude	NS
	Gomes- Osman et	27 ± 12.3 12 F, 2 M	Val/Val	8	iTBS	L M1 (FDI)	50 Hz	80% AMT	600 (3-pulse bursts repeated at 200 ms, 2-sec train of TBS for 192		Saliva	MEP amplitude	NS

	al. (2017)			Met allele						sec, intertrain	interval: 8 sec				nea
				carriers	6					1 ses	sion				
12	Jannati et	36.9±:	15.2	Val/Val	12	TDC		5.011	00% ANT	600 (3 pulses bu 200 ms fo	rsts repeated at or 40 sec)		MEP	Val/Met showed excitatory	h wa
13	al. (2017)	0 F, 18	3 M	Val/Met	6	CIR2	L MIT (FDI)	SUHZ	80% AMT	1 ses	sion	Sallva	amplitude	inhibitory protocol	nt do
		36.6±1	14.4 3 M	Val/Val	14								Motor threshold		http
14	Jannati et al. (2019)	37.8±:	15.4 M	Val/Met	8	cTBS	L M1 (FDI)	50Hz	80% AMT	600 (3 pulses bu 200ms fo 1 session, repeate retest reliability (rsts repeated at or 40 sec) ed twice for test- (7-33 days apart)	Saliva	MEP amplitude, Area under curve of MEP amplitude	Modulatory effects of cTBS were more reliable in Val/Val	ified by neer revi
		32.42 ± 1 8 F, 4	32.42 ± 11.24 8 F, 4 M		12					600 (3-pulse bursts repeated at 200 ms, 2-sec train of TBS for 192				Rest: NS and Rest: NS and Rest: NS and Rest: NS and Rest	1/202
15	Andrews et al. (2020)	39.25 ± 15.68 3 F, 5 M		Val/Met	iTBS		L M1 (FDI)	50Hz	80% AMT	sec, intertrain ii repeat 2 1 session per conditions in cc	nterval: 10 sec, 0 times) r condition, 3 punterbalanced	Saliva	MEP amplitude, SICI, ICF	exercise: NS High intensity exercise: Val/Val showed more excitatory modulatory effects following iTBS thang Val/Met.	4.11.06.24316 the author/fur
										order with at le	east 72 hr apart			Val/Met.	0617
		27.7 ± 2.8 16 F, 21 M		Val/Val	19						2-sec train for		MEP		; this
				Val/Met	15	iTBS	L M1 (FDI)	50Hz	80% AMT	1 session per	intertrain	Blood	amplitude, RMT, AMT		versio
16	Guerra et			Met/Met	3					condition, 4 conditions with	20 trains)				on po:
	al. (2020)	27.7 ± 2.8 16 F, 21 M		Val/Val	19	ствѕ	L M1 (FDI)			at least 7 days apart	600 (200 bursts for 40 sec) Blood		MEP	0 Inte	sted N
				Val/Met	15			50 Hz	80% AMT			Blood	amplitude,	NS NS	doven אפ xiv
				Met/Met	3									nal lic	י ber י
17	Harvey et	23.5 ± 12 F, 8	5.7 3 M	Val/Val	20			50 47	80% AMT	600 (triplets at 5 Hz for 40 sec)		Colline	MEP	Modulatory effects were	, 202
17	al. (2021)	25.5 ± 7.0 4 F, 7 M		Val/Met	11	CIDS		50112	30% AMT	1 ses	sion	Janva	amplitude	compared to Val/Val.	1. The
						_	Stroke (9	studies, 10	protocols)						lav th
	Mirowska-	lschemic stroke	12 F, 23 M	Val/Val	35		Hand paresis:								/right
		Hand paresis (N = 26):	5 F, 6 M	Met allele carriers	11		contralesional hemisphere of	1 Hz	90% RMT	1800/sessic	on (30 min)		BDNF	Val66Met: NS	holde
18	Guzel et al. (2013)	(N = 26): 62.73 ± 12.84	16 F, 24 M	c/c	40	rTMS	hand motor cortex		•	15 sessions over protocol of Senio	r 3 weeks [Cited ów et al. (2013)]	Blood	concentrati on		n for t
(2		Aphasia (N = 20): 61.25 ± 10.66	1 F, 5 M	C/T	6		cortex Aphasia: right Broca's	Sham (s	ham coi∣)	Total pulses: 27000			on	C270T: NS	his preprin veti itv

19	Chang et al. (2014)	< 2 weeks post stroke with moderate to severe unilateral upper extremity motor involvement	58.4 ± 9.6 4 F, 5 M 53.4 ± 13.7 15 F, 20 M	Val/Val Met allele carriers	9 35	- rTMS	lpsilesional M1 (Hand, no muscle specified)	10 Hz	90% RMT	1000/session (50 trains, intertrain interval: 55 sec) 10 sessions over 2 weeks Total pulses: 10000	Blood	FMA-UL FMA-LL BBT	Val/Val showed greater improvement compared to Met carriers NS Val/Val showed greater improvement compared to Met carriers
		Post stroke	dysmnesia	Val/Val	14			1 Ц-	100% MT	600/session (30 sequences of 20 pulses)		ΜοϹΑ	NS NS
20	Lu et al. (2015)	44.9 ±	44.9 ± 11.1		11	rTMS	R DLPFC	1 112	100% 1011	20 sessions over 4 weeks	Blood	LOTCA	
		15F,	25M	Val/Met	15			Sham (coi	l tilted 90°)	Total pulses: 12000		RBMT	NS may
21	Uhm et al. (2015)	> 6 months post stroke with	63.8±6.3 0 F, 6 M	Val/Val	6	rTMS	lpsilesional M1 (FDI)	10 Hz	Sub- threshold: 90% RMT	1000/session (20 trains of 5 sec stimulation, intertrain interval: 55 sec)	Blood	MEP amplitude	Val/Val showed higher increase in MEP amplitude with supra-threshold rTMS compared to sub-threshold rDMS rTMS. Met carriers showed no er differences of MEP amplitude between sub- and supra-threshold rTMS.
	· · ·	hemiparesis	55.3 ± 11.1 6 F, 10 M	Met allele carriers	16	_			Supra- threshold: 110% RMT Sham (coil tilted 90°, 90% RMT)	1 session per condition		MEP latency RMT	NS NS NS NS NS NS NS NS
		Val/Val							50% (((())))			FMA-UL,	dRxiv matic
22	Chang et al. (2016)	< 4 weeks post hemiparesis, r severe upper motor invo 56.7 ± 30F, 3	stroke with noderate to extremity lvement 13.0 2M	Met allele carriers	50	rTMS	lpsilesional M1 (FDI)	10 Hz	90% RMT	1,000/session (20 trains, intertrain interval: 55 sec) 10 sessions over 2 weeks Total pulses: 10000	B∣ood	FMA-LL, FMA-T Good responders (FMA-UL was ≥5 points) vs poor responders (FMA-UL was <5 points)	Good responders showed acress to display the propertion of val/Val compared to poor. Val/Val compared to poor. Val/Val were 1.80 times more likely than Met allele carriers to be associated with motor improvement.
23	Niimi et al. (2016)	N/A	Val/Val Met allele carriers	N = 95, genotype data N/A	rTMS	Contralesional M1 (FDI)	1 Hz	90% MT	1200/session x 2 sessions/day 22 sessions over 11 days Total pulses: 26400	Blood	FMA WMFT	NS Preprint NS NS	

$ \begin{array}{ c c c c c c c } \hline \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ $	Di Lazzaro 24 et al. (2015)	< 10 days post MCA ischemic stroke 64.15 ± 2.4	4F, 8M 5F, 3M	Val/Val Met allele carriers	12 8	iTBS	psilesional M1 (FDI)	50 Hz	80% AMT	600 (5 Hz every 10 of 3 pulses 1 ses) sec of 10 bursts s at 50Hz) sion	Blood	RMT, AMT, MEP amplitude, laterality index	NS NS
$ \frac{1}{25} $ $ \frac{1}{26} $ $ \frac{1}{2022} $ $ \frac{1}{1000000} $ $ \frac{1}{10000000000000000000000000000000000$	Parchure et	> 6 months post singular left	54.8 ± 13.9 2 F, 6 M	Val/Val	8	TRC		50.0	00% 4447	600 (50Hz triplets of pulses at 5Hz				Inhibitory modulatory effects lasted 30 min post-
$ \begin{array}{ c c c c c c c c c } \hline Pesane t \\ \hline Pesane t \\ al. (2022) \\ \hline Pesane t \\ bemisphere \\ ischemic \\ stroke \\ \hline \end{array} \begin{array}{ c c c c c c c c c c c c c c c c c c c$	²⁵ al. (2022)	hemisphere ischemic stroke	58±13.9 0 F, 10 M	Val/Met	10	- CIBS	K M1 (FD!)	50 Hz		1 ses	Saliva	LNMEP	observed in Val/Met until 30 min after.	
$ \frac{1}{26} \frac{1}{2023} \frac{1}$		>6 months	54.8±13.9 2 F, 6 M	Val/Val	8					C00/F0.Uz.trin	ate of pulses at			Aphasia was less severe in a Val/Val than Val/Met.
$ 27 \frac{1}{28} \frac{1}{400} \frac{1}{100} \frac{1}{10} \frac{1}{10} \frac{1}{100} \frac{1}{10} \frac{1}{$	26 Dresang et al. (2022)	left hemisphere ischemic stroke	58±13.9 0 F, 10 M	Val/Met	10	cTBS	R M1 (FDI)	50 Hz	80% AMT	5 Strain Sector Strain Sector Se		Saliva	WAB-AQ	Less severe aphasia was a var associated with more inhibitory modulatory effects in Val/Val than Val/Met.
$ \frac{1}{27} \left \begin{array}{c} \frac{1}{300} \\ \frac{1}{30} \\ \frac{1}{$							Depressio	n (3 studies, 5	protocols)				r a C	
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$	Deschie	Drug resistant mood disorders (31 major depression + 5 bipolar disorder in depressive	56.10± 13.71 17 F, 3 M	Val/Val	20	rTMS		1 Hz	110% MT	400/session (trains of 10 sec, intertrain interval: 20 sec)	5 sessions per condition over 5 days			Val/Val showed more
$\frac{1}{28} \frac{1}{1000} $	27 Chiavetto et al. (2008)		najor ression + bipolar 64.13 ± order in 11.53 pressive 12 F, 4 M	Met allele carriers	16		L DLPFC	17 Hz	110% MT	408/session (trains of 3 sec, intertrain interval: 120 sec)	[Cited protocol of Miniussi et al. (2005)] Total pulses:	Blood	HAMD	symptovement in depression and symptoms than Met allele 4 de carriers following rTMS (equivalent efficacy with the both 1 Hz and 17 Hz).
$\begin{array}{ c c c c c c } & & & & & & & & & & & & & & & & & & &$		phase)	,					Sham (coil 40%	flipped 180°, 6 MT)	N/A	2000			tional I
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$		Treatment resistant	50.7 ± 7.3	Val/Val	5	_		1 Hz	110%	300/session (5 trains of 60 stimuli,			HDRS Clinical	Val/Val were more likely togo
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	Krstić et al.	unipolar major	11 F, U M	Val/Met	6	rTMS			RIMT	intertrain int	erval: 3 min)	Blood	Global	achieve long-term · O sustained remission with
$\frac{1}{t_{s}} = \frac{1}{t_{s}} \frac{1}{t_{s}} \frac{1}{t_{s}} = \frac{1}{t_{s}} \frac{1}{t_{s}} \frac{1}{t_{s}} = \frac{1}{t_{s}} \frac{1}{t_{s}$	(2014)	depression on stable	46.1 ± 8.5	Val/Val	7		K DLPPC	Sham (coi	l tilted 90°,	10 sessions o	wer 2 weeks	ыооч	Scale - Severity of	rTMS than Met allele and carriers (4/5 vs. 1/5,
46.65 ± Val/Val 3 1800/session (3 10 sessions Medication 14.49 3 pulse bursts over 2 weeks iTl		antidepressan ts	8 F, U M	Val/Met	1			60%	RMT)	Total puls	ses: 3000		Illness	respectively).
		Medication	46.65 ± 14.49	Val/Val	3	iTBS		50 Hz	80% AMT	1800/session (3 pulse bursts	10 sessions over 2 weeks			iTBS: NS
29 Cheng et al. (2022) resistant depression 17 F, 9 M Met allele carriers 23 L DLPFC Down every 200ms/5 Hz) Total pulses: Blood HDRS-17 rTMS: Depr more in Val	29 Cheng et al. (2022)	resistant depression	17 F, 9 M	Met allele carriers	23	1182	L DLPFC		80% AMT	every 200m s/5 Hz)	Total pulses:	Blood	HDRS-17	rTMS: Depression reduced more in Val/Val compared
48.17 ± Val/Val 3 rTMS 10 Hz 100% 1600/session rTMS: 16000 to Met al			48.17 ±	Val/Val	3	rTMS		10 Hz	100%	1600/session	rTMS: 18000 rTMS: 16000			to Met allele carriers.

			14.12 15 F, 8 M 45.38± 12.38 21 F, 5 M	Met allele carriers Val/Val Met allele carriers	20 8 18	Sham		Sham coil wi	RMT using protocol th random ass	(40 trains of 4 sec stimulation, intertrain interval: 26 sec) s of iTBS or rTMS signment				(which was not ce
							Others	s (6 studies, 7	protocols)					
			51.7 ± 9.4 0 F, 70 M	c/c	70			Unspecifi ed high frequency	110% MT	Pulse nur	nber N/A		Repeatable Battery for the	Immediate memory
30	Su et al. (2023)	Veterans with Schizophrenia	55.7±8.6 0 F, 39 M	T allele carriers	39	rTMS	L DLPFC	Sham (s	20 sessions over 4 weeks (sham coil) Total pulses: N/A		Blood	Assessmen t of Neuropsyc hological Status	improved more in CC is homozygotes than in T ad allele carriers. 6 allela additional additional additional additional additional additional additionadditionadditaditionad additaditionadditionad additionad addi	
	Fried et al.	Mild-to- moderate Alzheimer's disease	67.7±6.9 5 F, 4 M	BDNF polymorp hism subtype	4					600 (2-sec train o 200ms with 30 j repeated 20 tin interval	of 3 pulses every oulses per train, mes, intertrain : 8 sec)		MEP amplitudes	Met allele carriers showedder a greater absolute changes a post iTBS than Val/Val.
31	(2017)	Type-2 diabetes	63.4± 7.3 6 F, 9 M	data in Val/Val	10	itbs		50 Hz	80% AMT	1 session, repeat	ed twice for test-	Saliva	RMT AMT	Intraindividual variability
		Healthy controls	58.6± 9.1 6 F, 6 M	and Val/Met N/A**	10					retest reliability days	with median 14 apart			carriers than in Val/Val. 20
		Gilles de la Tourette	14 F, 23 M	Val/Val	37					600 (3 bursts at			MEP amplitude – GTS	NS NS NS
		syndrome (GTS) 35.0±14.0	3 F, 10 M	Met allele carriers	13	iTBS		50 Hz	80% AMT	50 Hz, repeated at 5 Hz)	1 session per		MEP amplitude – Controls	iTBS and cTBS induced greater changes in Val/Valation compared to Met allele carriers.
32	Marsill et al. (2017)	Contr	els	Val/Val	36		L M1 (FDI)			600	condition, 2 conditions in random order	Blood	Yale Global Tic Severity Scale	NS .
		32.0± 18 F, 3	13.0 2 M	Met allele carriers	14	cTBS		50 Hz	80% AMT	(continuous train lasting 40 sec)			Yale– Brown Obsessive– Compulsive Scale	display splay the ns the pr
33	Sanna et al. (2020)	Parkinson's Disease with Levodopa- induced Dyskinesias (LID)	6M, 1 F	Val/Val	7	cTBS	Lateral cerebellum ipsilateral to the LID	50 Hz	80% AMT	600 (3 bursts at ms/! 1 session per conditions with o random order (c	50 Hz every 200 5Hz) condition, 2 ne week apart in rossover design)	Blood	Core Assessmen t Program for Surgical Interventio nal Therapies	nhibitory cTBS decreased dyskinesia in Val/Val but not in Val/Met.

		68.09 ± 8.8										dyskinesia score	(which
			2M, 2F	Val/Met	4	-		Sham (coi 40%	l tilted 90°, AMT)	-		Serum BDNF	Inhibitory cTBS decreased serum BDNF in Val/Val but not in Val/Met.
		High- functioning	39.9 ± 14.0 2 F, 6 M	Val/Val	8								tified
34	Jannati et al. (2021)	adults with non- syndromic Autism Spectrum Disorder (ASD)	35.7 ± 9.1 0 F, 9 M	Met allele carriers	9	cTBS	L M1 (FDI)	50 Hz	80% AMT	600 (triplet pulses of 200 bursts every 200 ms for 40 sec) 1 session	Saliva	MEP amplitude	No differences of cTBS responses bet ween ASD and controls in Val/Val.
		Controls	34.0 ± 13.7 4F, 19 M	Val/Val	23								in Met carriers.
		Controis	39.9 ± 14.0 3 F, 13 M	Met allele carriers	16								e unde
35	Sanna et al.	Spinocerebell ar Ataxia 38 (SCA 38)	1F, 2M	Val/Val	3	iTBS	Cerebellum (1 cm inferior and 3 cm	50 Hz Sham (coil tilted 90°, 40% AMT)	80% AMT	1,200/session (3 bursts at 50 Hz every 200 ms/5Hz, 20 2-sec trains repeated every 10 sec, 2-min pause between left- and right-side stimulation with 600 stimuli/side)	Blood	Modified Internation al Cooperativ e Ataxia Rating Scale	ar a CC-BY-NC-ND 4
	35 (2022)	50.33 ± 4.93					left/right to the inion)			10 sessions over 10 days in random order (crossover design)		MEP amplitude	NS NS
			2F, 1M	Val/Met	3			Sham (coil tilted 90° 40% AMT)		% AMT) Total pulses: 12000		Serum BDNF	Excitatory iTBS increased matrix serum BDNF in Val/Val buttoral decreased serum BDNF in lice Val/Met.

F: females, M: males, L: left, R: right, M1: primary motor cortex, DLPFC: dorsal lateral prefrontal cortex, FDI: first dorsal interosseous, ADM: abductor digiti minimi, RMT: resting motor threshold, AMT: active motor threshold, rTMS: repetitive transcranial magnetic stimulation, iTBS: intermittent theta-burst stimulation, cTBS: continuous theta-burst stimulation, BDNF: brain-derived neurotrophic factor, MEP: motor evoked potential, LnMEP: Natural log- transformed MEP, SICI: short-interval intracortical inhibition, ICF: intracortical facilitation, FMA: Fugl Meyer Assessment, FMA-UL: Fugl Meyer Assessment-Upper Limb, FMA-LL: Fugl Meyer Assessment-Lower Limb, FMA-T: Fugl Meyer Assessment-Total, BBT: Box and Block Test, MoCA: Montreal Cognitive Assessment, LOTCA: Loewenstein Occupational Therapy Cognitive Assessment, RBMT: Rivermead Behavioral Memory Test, fMRI BOLD activation: functional magnetic resonance imaging blood oxygen level-dependent activation, WAB-AQ: Western Aphasia Battery-Aphasia Quotient, HAMD and HDRS: Hamilton Depression Rating Scale, NS: non-significant, N/A: not available

** not all participants provided saliva sample for genotyping



Reason 1: conference abstracts (N=16) Reason 2: reviews/commentaries (N=18) Reason 3: rTMS or TBS not used (N=32) Reason 4: article not in English (N=2) Reason 5: protocol registrations (N=6) Reason 6: animal studies (N=5)

Reason: all participants had the



Random sequence generation Allocation concealment Blinding of participants and researchers Blinding of outcome assessment Incomplete outcome data Selective reporting Other bias

nedRxiv preprint doi: https://doi.org/10.1101/2024.11.06.24316617; this version posted November 7, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

> Random sequence generation Allocation concealment Blinding of participants and researchers Blinding of outcome assessment Incomplete outcome data Selective reporting Other bias

A. Healthy





Iow risk of bias



unclear risk of bias

high risk of bias